FDA Approves Another Drug for Treating Acute Infections

Orbactiv is approved for treating patients with MRSA and some other bacteria.

The U.S. Food and Drug Administration approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with acute bacterial skin infections, including Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains), various Streptococcus species, and Enterococcus faecalis, on Aug. 6. The drug is administered intravenously. It is marketed by The Medicines Company, based in Parsippany, N.J.

Orbactiv is the third new antibacterial drug FDA has approved this year to treat such infections; the others are Dalvance (dalbavancin) and Sivextro (tedizolid). "The approval of several new antibacterial drugs this year demonstrates that we are making progress in increasing the availability of treatment options for patients and physicians," said Dr. Edward Cox, M.D., MPH, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. "However, more work is needed in this area, and the FDA remains a committed partner to help promote the development of antibacterial drugs."

Orbactiv also is the third new drug designated as a Qualified Infectious Disease Product to receive FDA approval. Under the Generating Antibiotic Incentives Now title of the FDA Safety and Innovation Act, Orbactiv was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat a serious or life-threatening infection.

According to FDA's news release, the most common side effects identified in clinical trials of the drug were headache, nausea, vomiting, the formation of skin and soft tissue abscesses on arms and legs, and diarrhea. Orbactiv's label includes a warning about interference with coagulation tests and interaction with warfarin, a drug that is used to prevent blood clots.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2022

    June 2022

    Featuring:

    • SAFETY CULTURE
      Corporate Safety Culture Is Workplace Culture
    • HEAT STRESS
      Keeping Workers Safe from Heat-Related Illnesses & Injuries
    • EMPLOYEE HEALTH SCREENING
      Should Employers Consider Oral Fluid Drug Testing?
    • PPE FOR WOMEN
      Addressing Physical Differences
    View This Issue